餐后高脂血症及其治疗的研究进展

doi:10.12114/j.issn.1007-9572.2025.0317

中国全科医学 ›› 2026, Vol. 29 ›› Issue (18): 2546-2553.DOI: 10.12114/j.issn.1007-9572.2025.0317

• 论著·热点研究·代谢异常 • 上一篇

餐后高脂血症及其治疗的研究进展

刘岱岳¹^,²^,³, 刘新灿¹^,²^,^*(), 兰真真¹^,²

1．450000　河南省郑州市，河南中医药大学第一附属医院心脏中心
2．450000　河南省郑州市，中西医防治重大疾病河南省协同创新中心
3．450046　河南省郑州市，河南中医药大学第一临床医学院

收稿日期:2025-08-07 修回日期:2025-12-25 出版日期:2026-06-20 发布日期:2026-05-21
通讯作者: 刘新灿
作者贡献：
刘岱岳负责撰写文章、文献检索；刘新灿负责文章的构思、设计与审校，对文章整体负责；兰真真负责文章修改。
基金资助:
国家自然科学基金资助项目(82374269)

Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches

LIU Daiyue¹^,²^,³, LIU Xincan¹^,²^,^*(), LAN Zhenzhen¹^,²

1. Heart Center, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
2. Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Zhengzhou 450000, China
3. Henan University of Traditional Chinese Medicine First Clinical Medical College, Zhengzhou 450046, China

Received:2025-08-07 Revised:2025-12-25 Published:2026-06-20 Online:2026-05-21
Contact: LIU Xincan

分享到

摘要/Abstract

摘要： 高脂血症可并发诸多心血管及代谢疾病，对人类健康威胁日益严重。临床上常以清晨空腹血脂水平来定义血脂水平，但真实世界中人体绝大部分时间并非处于空腹状态，单纯检测空腹血脂水平难以反映体内脂代谢的全貌。近年来国内外多项研究以餐后高脂血症为核心，探讨了关于其诊断及治疗等多个方面。本文对餐后高脂血症的评价方法、诱因、并发症及治疗方法的最新研究进行了综述，以期对临床上餐后高脂血症的诊断及治疗提供参考和帮助。

关键词: 高脂血症, 餐后高脂血症, 口服脂肪负荷试验, 甘油三酯, 餐后高血糖, 动脉粥样硬化

Abstract:

Hyperlipidemia can be complicated by various cardiovascular and metabolic diseases, posing an increasingly serious threat to human health. Clinically, blood lipid levels are often defined based on fasting blood levels in the early morning. However, in the real world, the human body is not in a fasting state for most of the time, and simply detecting fasting blood lipid levels is difficult to reflect the full picture of lipid metabolism in the body. In recent years, multiple studies at home and abroad have focused on postprandial hyperlipidemia, exploring various aspects such as its diagnosis and treatment. This article reviews the latest research on the evaluation methods, inducing factors, complications, and treatment approaches of postprandial hyperlipidemia, aiming to provide reference and assistance for the clinical diagnosis and treatment of postprandial hyperlipidemia.

Key words: Hyperlipidemias, Postprandial hyperlipidemia, Oral fat tolerance test, Triglyceride, Postprandial hyperglycaemia, Atherosclerosis

刘岱岳,刘新灿,兰真真. 餐后高脂血症及其治疗的研究进展[J]. 中国全科医学, 2026, 29(18): 2546-2553. DOI: 10.12114/j.issn.1007-9572.2025.0317.
LIU Daiyue,LIU Xincan,LAN Zhenzhen. Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches[J]. Chinese General Practice, 2026, 29(18): 2546-2553. DOI: 10.12114/j.issn.1007-9572.2025.0317.

参考文献 67

[1]	国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2024概要[J]. 中国循环杂志, 2025, 40(6): 521-559. DOI: 10.3969/j.issn.1000-3614.2025.06.001.
[2]	PATSCH J R, MIESENBÖCK G, HOPFERWIESER T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state[J]. Arterioscler Thromb, 1992, 12(11): 1336-1345. DOI: 10.1161/01.atv.12.11.1336.
[3]	NIKKILÄ M, SOLAKIVI T, LEHTIMÄKI T, et al. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease[J]. Atherosclerosis, 1994, 106(2): 149-157. DOI: 10.1016/0021-9150(94)90120-1.
[4]	NAKAMURA K, MIYOSHI T, YUNOKI K, et al. Postprandial hyperlipidemia as a potential residual risk factor[J]. J Cardiol, 2016, 67(4): 335-339. DOI: 10.1016/j.jjcc.2015.12.001.
[5]	ALDRED H E, PERRY I C, HARDMAN A E. The effect of a single bout of brisk walking on postprandial lipemia in normolipidemic young adults[J]. Metabolism, 1994, 43(7): 836-841. DOI: 10.1016/0026-0495(94)90263-1.
[6]	MASUDA D, YAMASHITA S. Postprandial hyperlipidemia and remnant lipoproteins[J]. J Atheroscler Thromb, 2017, 24(2): 95-109. DOI: 10.5551/jat.rv16003.
[7]	HAVEL R J. Remnant lipoproteins as therapeutic targets[J]. Curr Opin Lipidol, 2000, 11(6): 615-620. DOI: 10.1097/00041433-200012000-00008.
[8]	ZILVERSMIT D B. Atherogenesis: a postprandial phenomenon[J]. Circulation, 1979, 60(3): 473-485. DOI: 10.1161/01.cir.60.3.473.
[9]	NAKAJIMA K, NAKANO T, TOKITA Y, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons[J]. Clin Chim Acta, 2011, 412(15/16): 1306-1318. DOI: 10.1016/j.cca.2011.04.018.
[10]	NAKAJIMA K, SAITO T, TAMURA A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels[J]. Clin Chim Acta, 1993, 223(1/2): 53-71. DOI: 10.1016/0009-8981(93)90062-9.
[11]	KAHRI J, FRUCHART-NAJIB J, MATIKAINEN N, et al. The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity[J]. Diabetes Care, 2007, 30(8): 2083-2085. DOI: 10.2337/dc07-0100.
[12]	YANAI H, ADACHI H, HAKOSHIMA M, et al. Atherogenic lipoproteins for the statin residual cardiovascular disease risk[J]. Int J Mol Sci, 2022, 23(21): 13499. DOI: 10.3390/ijms232113499.
[13]	KATSIKI N, FILIPPATOS T, VLACHOPOULOS C, et al. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023[J]. Atheroscler Plus, 2024, 55: 74-92. DOI: 10.1016/j.athplu.2024.01.004.
[14]	MASUDA D, NAKAGAWA-TOYAMA Y, NAKATANI K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia[J]. Eur J Clin Invest, 2009, 39(8): 689-698. DOI: 10.1111/j.1365-2362.2009.02163.x.
[15]	NAKAJIMA K, NAKANO T, TOKITA Y, et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma[J]. Clin Chim Acta, 2012, 413(13/14): 1077-1086. DOI: 10.1016/j.cca.2012.02.026.
[16]	YANAI H, ADACHI H, HAKOSHIMA M, et al. Postprandial hyperlipidemia: its pathophysiology, diagnosis, atherogenesis, and treatments[J]. Int J Mol Sci, 2023, 24(18): 13942. DOI: 10.3390/ijms241813942.
[17]	ISO H, NAITO Y, SATO S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women[J]. Am J Epidemiol, 2001, 153(5): 490-499. DOI: 10.1093/aje/153.5.490.
[18]	EBERLY L E, STAMLER J, NEATON J D, et al. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease[J]. Arch Intern Med, 2003, 163(9): 1077-1083. DOI: 10.1001/archinte.163.9.1077.
[19]	OKAMURA T, TSUKAMOTO K, ARAI H, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022[J]. J Atheroscler Thromb, 2024, 31(6): 641-853. DOI: 10.5551/jat.GL2022.
[20]	MASUDA D, SAKAI N, SUGIMOTO T, et al. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia[J]. J Atheroscler Thromb, 2011, 18(12): 1062-1070. DOI: 10.5551/jat.10470.
[21]	MARCOUX C, TREMBLAY M, NAKAJIMA K, et al. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of typeⅢ and typeⅣ hyperlipoproteinemic patients[J]. J Lipid Res, 1999, 40(4): 636-647.
[22]	YOSHIDA H, KUROSAWA H, HIROWATARI Y, et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C)[J]. Lipids Health Dis, 2008, 7: 18. DOI: 10.1186/1476-511X-7-18.
[23]	MIYAUCHI K, KAYAHARA N, ISHIGAMI M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol[J]. Clin Chem, 2007, 53(12): 2128-2135. DOI: 10.1373/clinchem.2007.092296.
[24]	MAHLEY R W, HUANG Y, RALL S C Jr. Pathogenesis of type Ⅲ hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes[J]. J Lipid Res, 1999, 40(11): 1933-1949.
[25]	GOLDSTEIN J L, SCHROTT H G, HAZZARD W R, et al. Hyperlipidemia in coronary heart disease.Ⅱ. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia[J]. J Clin Invest, 1973, 52(7): 1544-1568. DOI: 10.1172/JCI107332.
[26]	SHOJI T, EMOTO M, KAWAGISHI T, et al. Atherogenic lipoprotein changes in diabetic nephropathy[J]. Atherosclerosis, 2001, 156(2): 425-433. DOI: 10.1016/S0021-9150(00)00673-0.
[27]	林成, 唐志家, 沈茜.糖耐量减低人群TG/HDL-C, TyG及衍生指标与颈动脉粥样硬化关系[J].国际检验医学杂志, 2024, 45(22):2710-2715.
[28]	徐兰梦, 黄榆智, 韩玉竹, 等. 肠道微生物调控脂肪沉积及其代谢相关疾病的研究进展[J]. 畜牧兽医学报, 2024, 55(10):4263-4277. DOI:10.11843/j.issn.0366-6964.2024.10.003.
[29]	AI M, TANAKA A, OGITA K, et al. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes[J]. J Am Coll Cardiol, 2001, 38(6): 1628-1632. DOI: 10.1016/s0735-1097(01)01611-4.
[30]	徐海. 紫苏油对动脉粥样硬化模型动物脂质代谢的干预作用[D]. 重庆: 重庆三峡学院, 2024.
[31]	史菊, 黄小丽, 王宇甜, 等. 小而密低密度脂蛋白胆固醇与冠状动脉病变程度的相关性分析[J]. 中国实用医药, 2024, 19(18): 51-55. DOI: 10.14163/j.cnki.11-5547/r.2024.18.012.
[32]	谭艳美, 陈三俊, 谭玉林, 等. PLIN2在氧化型低密度脂蛋白诱导的泡沫细胞脂噬中的作用[J]. 现代医药卫生, 2023, 39(23): 3966-3969, 3976. DOI: 10.3969/j.issn.1009-5519.2023.23.002.
[33]	O'KEEFE J H, GHEEWALA N M, O'KEEFE J O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health[J]. J Am Coll Cardiol, 2008, 51(3): 249-255. DOI: 10.1016/j.jacc.2007.10.016.
[34]	LEARY M, TANAKA H. Role of fluid milk in attenuating postprandial hyperglycemia and hypertriglyceridemia[J]. Nutrients, 2020, 12(12): 3806. DOI: 10.3390/nu12123806.
[35]	PETRIDOU A, MOUGIOS V. Exercise to lower postprandial lipemia: why, when, what and how[J]. Int J Sports Med, 2022, 43(12): 1013-1022. DOI: 10.1055/a-1810-5118.
[36]	HEALY G N, DUNSTAN D W, SALMON J, et al. Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose[J]. Diabetes Care, 2007, 30(6): 1384-1389. DOI: 10.2337/dc07-0114.
[37]	ROBERTS M J, THACKRAY A E, WADLEY A J, et al. Effect of acute walking on endothelial function and postprandial lipemia in south asians and white Europeans[J]. Med Sci Sports Exerc, 2023, 55(5): 794-802. DOI: 10.1249/MSS.0000000000003098.
[38]	YAMASHITA S, ARAI H, YOKOTE K, et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia[J]. J Clin Lipidol, 2018, 12(5): 1267-1279.e4. DOI: 10.1016/j.jacl.2018.06.010.
[39]	CAVALLERO E, DACHET C, ASSADOLAHI F, et al. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control[J]. Atherosclerosis, 2003, 166(1): 151-161. DOI: 10.1016/s0021-9150(02)00321-0.
[40]	JR J G, NGUYEN N H, THEROUX P, et al. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state[J]. J Cardiovasc Pharmacol, 2000, 35(1): 164-172. DOI: 10.1097/00005344-200001000-00022.
[41]	Chinese Medical Association Geriatrics Branch. Expert consensus on the application of ω-3 fatty acid prescription drugs in aging-related diseases (2024 edition)[J]. Zhonghua Yi Xue Za Zhi, 2024, 104(9): 635-649. DOI: 10.3760/cma.j.cn112137-20231018-00809.
[42]	AUSTIN G, FERGUSON J J, THOTA R N, et al. Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study[J]. Clin Nutr, 2021, 40(2): 420-427. DOI: 10.1016/j.clnu.2020.06.027.
[43]	SPAGNUOLO C M, HEGELE R A. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-Ⅲ inhibitors[J]. Expert Opin Pharmacother, 2023, 24(9): 1013-1020. DOI: 10.1080/14656566.2023.2206015.
[44]	GOUNI-BERTHOLD I, SCHWARZ J, BERTHOLD H K. Updates in drug treatment of severe hypertriglyceridemia[J]. Curr Atheroscler Rep, 2023, 25(10): 701-709. DOI: 10.1007/s11883-023-01140-z.
[45]	GOUNI-BERTHOLD I, ALEXANDER V J, YANG Q Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Diabetes Endocrinol, 2021, 9(5): 264-275. DOI: 10.1016/S2213-8587(21)00046-2.
[46]	HEGELE R A. Apolipoprotein C-Ⅲ inhibition to lower triglycerides: one ring to rule them all?[J]. Eur Heart J, 2022, 43(14): 1413-1415. DOI: 10.1093/eurheartj/ehab890.
[47]	TARDIF J C, KARWATOWSKA-PROKOPCZUK E, AMOUR E S, et al. Apolipoprotein C-Ⅲ reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk[J]. Eur Heart J, 2022, 43(14): 1401-1412. DOI: 10.1093/eurheartj/ehab820.
[48]	CLIFTON P, SULLIVAN D, BAKER J, et al. Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia[J]. Circulation, 2021, 144(Suppl_1): A10357-A. DOI: 10.1161/circ.144.suppl_1.10357
[49]	BALLANTYNE C M, VASAS S, AZIZAD M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia[J]. N Engl J Med, 2024, 391(10): 899-912. DOI: 10.1056/NEJMoa2404143.
[50]	RAY K K, WRIGHT R S, KALLEND D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519. DOI: 10.1056/NEJMoa1912387.
[51]	FITZGERALD K, WHITE S, BORODOVSKY A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa1609243.
[52]	PADAM P, BARTON L, WILSON S, et al. Lipid lowering with inclisiran: a real-world single-centre experience[J]. Open Heart, 2022, 9(2): e002184. DOI: 10.1136/openhrt-2022-002184.
[53]	黎华, 黎静, 杨云飞, 等. 他汀类药物作用机制及临床应用进展[J]. 中国老年保健医学, 2023, 21(6): 116-119. DOI: 10.3969/j.issn.1672-2671.2023.06.024.
[54]	BYRNE P, DEMASI M, JONES M, et al. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis[J]. JAMA Intern Med, 2022, 182(5): 474-481. DOI: 10.1001/jamainternmed.2022.0134.
[55]	ALVAREZ-JIMENEZ L, MORENO-CABAÑAS A, RAMIREZ-JIMENEZ M, et al. Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: a systematic review and network meta-analysis[J]. J Sport Health Sci, 2022, 11(5): 567-577. DOI: 10.1016/j.jshs.2021.07.006.
[56]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255. DOI: 10.3760/cma.j.cn112148-20230119-00038.
[57]	NAKAMURA A, SATO K, KANAZAWA M, et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease[J]. Heart Vessels, 2019, 34(6): 916-925. DOI: 10.1007/s00380-018-1319-x.
[58]	HAN Y L, CHEN J Y, CHOPRA V K, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand[J]. J Clin Lipidol, 2020, 14(1): 98-108.e8. DOI: 10.1016/j.jacl.2019.10.015.
[59]	WEINTRAUB M S, CHARACH G, GROSSKOPF I. Effects of fibric acid derivatives and metformin on postprandial lipemia[J]. Atherosclerosis, 1998, 141(Suppl 1): S71-S75. DOI: 10.1016/s0021-9150(98)00221-4.
[60]	KADO S, MURAKAMI T, AOKI A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 1998, 41(1): 49-55. DOI: 10.1016/S0168-8227(98)00062-X.
[61]	ABBASI F, LAMENDOLA C, LEARY E T, et al. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers[J]. Diabetes Obes Metab, 2009, 11(8): 779-785. DOI: 10.1111/j.1463-1326.2009.01041.x.
[62]	NOVODVORSKÝ P, HALUZÍK M. The effect of GLP-1 receptor agonists on postprandial lipaemia[J]. Curr Atheroscler Rep, 2022, 24(1): 13-21. DOI: 10.1007/s11883-022-00982-3.
[63]	TASKINEN M R, BJÖRNSON E, MATIKAINEN N, et al. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(5): 1191-1201. DOI: 10.1111/dom.14328.
[64]	BUNCK M C, CORNÉR A, ELIASSON B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress[J]. Atherosclerosis, 2010, 212(1): 223-229. DOI: 10.1016/j.atherosclerosis.2010.04.024.
[65]	WANG S J, REN H H, ZHONG H Z, et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study[J]. Gut Microbes, 2022, 14(1): 2003176. DOI: 10.1080/19490976.2021.2003176.
[66]	MORROW N M, TRZASKALSKI N A, HANSON A A, et al. Nobiletin prevents high-fat diet-induced dysregulation of intestinal lipid metabolism and attenuates postprandial lipemia[J]. Arterioscler Thromb Vasc Biol, 2022, 42(2): 127-144. DOI: 10.1161/ATVBAHA.121.316896.
[67]	XU D Y, SHU J, HUANG Q Y, et al. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine[J]. Atherosclerosis, 2010, 211(1): 237-241. DOI: 10.1016/j.atherosclerosis.2010.01.044.

餐后高脂血症及其治疗的研究进展

Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 67

相关文章 15

编辑推荐

Metrics

留言

[1]	郑坤杰, 荣义华, 王雪静, 侯丽萍, 谷巍, 李晓龙, 侯晓宇, 宋光耀. 血清硫氧还蛋白相互作用蛋白与脂质代谢异常的相关性研究[J]. 中国全科医学, 2026, 29(15): 2037-2042.
[2]	刘紫阳, 金梦龙, 刘森, 魏梦伟, 苏比努尔·居热提, 付真彦. 新疆维吾尔自治区不同民族接受PCSK9抑制剂治疗后的血脂水平差异研究[J]. 中国全科医学, 2026, 29(12): 1579-1587.
[3]	刘洋, 梁芳, 吴玲, 李文磊, 李鹏飞. 非常规脂质以及甘油三酯-葡萄糖指数诊断初发急性缺血性脑卒中的价值研究[J]. 中国全科医学, 2026, 29(11): 1422-1429.
[4]	孙沁瑜, 邓毅凡, 杨天笑, 方震, 纪军, 何胜虎, 张晶. 糖化血红蛋白和载脂蛋白A-1比值、三酰甘油葡萄糖-体质指数及联合预测冠状动脉钙化严重程度的临床研究[J]. 中国全科医学, 2026, 29(09): 1137-1145.
[5]	中国医药教育协会心血管内科专业委员会, 中国医疗保健国际交流促进会心血管健康医学分会. 青年冠状动脉疾病的早期筛查和预防专家共识[J]. 中国全科医学, 2026, 29(02): 137-147.
[6]	范学明, 杨宁宁, 郑症, 吴玉梅, 王祺. 2型糖尿病合并代谢相关脂肪性肝病患者微血管病变发生的相关因素分析及预测价值研究[J]. 中国全科医学, 2025, 28(36): 4578-4585.
[7]	张姝, 程钰, 吴寿岭, 陈朔华, 吴云涛. 非糖尿病人群累积血浆致动脉粥样硬化指数暴露对新发心血管疾病影响的队列研究[J]. 中国全科医学, 2025, 28(36): 4558-4565.
[8]	王碧优, 高鹰, 尤俊方, 刘莉, 张卿, 苏海燕. 心血管疾病风险人群脂质比值与炎症指标的典型相关性研究[J]. 中国全科医学, 2025, 28(33): 4132-4139.
[9]	徐春艳, 贺玲, 郭灿辉, 赖胡榕, 廖彩凤, 涂怀军. 中国中老年人血脂水平与肌少症性肥胖发病风险的相关性：一项队列研究[J]. 中国全科医学, 2025, 28(33): 4125-4131.
[10]	廖姣姣, 王照宇, 李兆基, 赵威, 詹思延, 王鹏, 陶立元. 非高密度脂蛋白胆固醇动态变化对颈动脉内中膜增厚的预测价值：一项双向性队列研究[J]. 中国全科医学, 2025, 28(31): 3932-3941.
[11]	向心月, 张冰青, 欧阳煜钦, 汤文娟, 冯文焕. 短期内科门诊减重对肥胖患者动脉粥样硬化性心血管疾病风险的影响研究[J]. 中国全科医学, 2025, 28(26): 3229-3239.
[12]	高海钧, 任佳禹, 王若琳, 周慧亚, 曲鹏. 内皮细胞损伤及其功能障碍在动脉粥样硬化中作用的研究进展[J]. 中国全科医学, 2025, 28(21): 2697-2704.
[13]	褚田雨, 顾艳. 颈动脉钙化特征在评估斑块稳定性及临床事件中的作用[J]. 中国全科医学, 2025, 28(18): 2247-2252.
[14]	吕露露, 祝万洁, 肖明洋, 李祎珂, 张娟. 原发性高血压患者血压昼夜节律与血浆氧化的低密度脂蛋白/β2-糖蛋白I复合物及颈动脉粥样硬化的相关性研究[J]. 中国全科医学, 2025, 28(18): 2228-2233.
[15]	中华预防医学会糖尿病预防与控制专业委员会. 中国糖尿病行为与生活方式干预指南（2024版）[J]. 中国全科医学, 2025, 28(07): 777-796.